HSBC Holdings’s Kiniksa Pharmaceuticals KNSA Stock Holding History

HSBC Holdings’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$248K	Buy	+5,157	New	+$228K	﹤0.01%	2527
2025 Q4	–	Sell	-8,080	Closed	-$308K	–	3056
2025 Q3	$308K	Buy	+8,080	New	+$263K	﹤0.01%	2322
2025 Q2	–	Sell	-12,676	Closed	-$280K	–	3130
2025 Q1	$280K	Sell	12,676 -436	-3%	-$8.97K	﹤0.01%	2417
2024 Q4	$257K	Sell	13,112 -554	-4%	-$12.6K	﹤0.01%	2588
2024 Q3	$345K	Buy	+13,666	New	+$333K	﹤0.01%	2242
2024 Q2	–	Sell	-16,356	Closed	-$323K	–	3067
2024 Q1	$323K	Buy	+16,356	New	+$319K	﹤0.01%	2402
2021 Q4	–	Sell	-10,040	Closed	-$115K	–	3307
2021 Q3	$115K	Buy	+10,040	New	+$131K	﹤0.01%	2873
2019 Q4	–	Sell	-14,730	Closed	-$125K	–	3122
2019 Q3	$125K	Buy	+14,730	New	+$163K	﹤0.01%	2955

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

HSBC Holdings's KNSA Position: Q1 2026 in Review

HSBC Holdings opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q1 2026: 5,157 shares worth $248K. The stake represents ﹤0.01% of the portfolio and ranks #2527 among its holdings. This is a return to the name: HSBC Holdings previously reported a position in KNSA as recently as Q3 2025.

HSBC Holdings first reported a position in KNSA in Q3 2019 and has held it in 8 quarters since. The position peaked at $345K in Q3 2024. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

HSBC Holdings held 5,157 shares of Kiniksa Pharmaceuticals worth $248K as of Q1 2026.
Kiniksa Pharmaceuticals was a new HSBC Holdings position in Q1 2026.
Kiniksa Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2527 holding.
HSBC Holdings first reported a position in Kiniksa Pharmaceuticals in Q3 2019 and has held it in 8 quarters since.
HSBC Holdings's Kiniksa Pharmaceuticals position peaked at $345K in Q3 2024.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.